Takeda Pharmaceutical Company Limited 4502.T Stock
Takeda Pharmaceutical Company Limited Price Chart
Takeda Pharmaceutical Company Limited 4502.T Financial and Trading Overview
Takeda Pharmaceutical Company Limited stock price | 4094 JPY |
Previous Close | 4537 JPY |
Open | 4549 JPY |
Bid | 4567 JPY x 0 |
Ask | 4572 JPY x 0 |
Day's Range | 4532 - 4572 JPY |
52 Week Range | 3497 - 4629 JPY |
Volume | 6.3M JPY |
Avg. Volume | 4.6M JPY |
Market Cap | 7.14T JPY |
Beta (5Y Monthly) | 0.677011 |
PE Ratio (TTM) | 22.665081 |
EPS (TTM) | 112.36 JPY |
Forward Dividend & Yield | 188 (4.15%) |
Ex-Dividend Date | September 28, 2023 |
1y Target Est | 4772.5 JPY |
4502.T Valuation Measures
Enterprise Value | 11.44T JPY |
Trailing P/E | 22.665081 |
Forward P/E | 23.023466 |
PEG Ratio (5 yr expected) | 2.69 |
Price/Sales (ttm) | 1.7718569 |
Price/Book (mrq) | 1.1185346 |
Enterprise Value/Revenue | 2.84 |
Enterprise Value/EBITDA | 9.349 |
Trading Information
Takeda Pharmaceutical Company Limited Stock Price History
Beta (5Y Monthly) | 0.677011 |
52-Week Change | 27.73% |
S&P500 52-Week Change | 20.43% |
52 Week High | 4629 JPY |
52 Week Low | 3497 JPY |
50-Day Moving Average | 4508.58 JPY |
200-Day Moving Average | 4161.61 JPY |
4502.T Share Statistics
Avg. Volume (3 month) | 4.6M JPY |
Avg. Daily Volume (10-Days) | 3.95M JPY |
Shares Outstanding | 1.56B |
Float | 1.54B |
Short Ratio | N/A |
% Held by Insiders | 1.23% |
% Held by Institutions | 42.48% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 180 |
Trailing Annual Dividend Yield | 3.96% |
5 Year Average Dividend Yield | 465.00% |
Payout Ratio | 0.8914 |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | March 31, 2023 |
Most Recent Quarter (mrq) | March 31, 2023 |
Next Fiscal Year End | March 31, 2024 |
Profitability
Profit Margin | 7.87% |
Operating Margin (ttm) | 13.87% |
Gross Margin | 69.10% |
EBITDA Margin | 30.37% |
Management Effectiveness
Return on Assets (ttm) | 2.57% |
Return on Equity (ttm) | 5.26% |
Income Statement
Revenue (ttm) | 4.03T JPY |
Revenue Per Share (ttm) | 2595.35 JPY |
Quarterly Revenue Growth (yoy) | 9.50% |
Gross Profit (ttm) | N/A |
EBITDA | 1.22T JPY |
Net Income Avi to Common (ttm) | 317.02B JPY |
Diluted EPS (ttm) | 201.72 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 533.53B JPY |
Total Cash Per Share (mrq) | 343.21 JPY |
Total Debt (mrq) | 4.92T JPY |
Total Debt/Equity (mrq) | 77.37 JPY |
Current Ratio (mrq) | 0.966 |
Book Value Per Share (mrq) | 4087.491 |
Cash Flow Statement
Operating Cash Flow (ttm) | 977.16B JPY |
Levered Free Cash Flow (ttm) | 468.63B JPY |
Profile of Takeda Pharmaceutical Company Limited
Country | Japan |
State | N/A |
City | Tokyo |
Address | 1-1, Nihonbashi-Honcho 2-chome |
ZIP | 103-8668 |
Phone | 81 3 3278 2111 |
Website | https://www.takeda.com |
Industry | Drug Manufacturers-Specialty & Generic |
Sector(s) | Healthcare |
Full Time Employees | N/A |
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan, the United States, Europe, Canada, Latin America, Russia, rest of Asia, and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab, Alofisel, Dexilant, Natpara, Adynovate/Adynovi, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Velcade, Leuplin/Enantone, Adcetris, Vyvansese, Trintellix, and Alunbrig brands. Takeda Pharmaceutical Company Limited has out-licensing agreement with Neurocrine Biosciences, Inc.; collaborations and in-licensing agreements with the University of Texas MD Anderson Cancer Center, Arrowhead Pharmaceuticals Inc., and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., ZEDIRA GmbH, and Dr. Falk Pharma GmbH, as well as a licensing agreement with ProThera Biologics Inc. It also has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, Selecta Biosciences, BridGene Biosciences, Skyhawk Therapeutics, and StrideBio; and strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
Q&A For Takeda Pharmaceutical Company Limited Stock
What is a current 4502.T stock price?
Takeda Pharmaceutical Company Limited 4502.T stock price today per share is 4094 JPY.
How to purchase Takeda Pharmaceutical Company Limited stock?
You can buy 4502.T shares on the Tokyo exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Takeda Pharmaceutical Company Limited?
The stock symbol or ticker of Takeda Pharmaceutical Company Limited is 4502.T.
Which industry does the Takeda Pharmaceutical Company Limited company belong to?
The Takeda Pharmaceutical Company Limited industry is Drug Manufacturers-Specialty & Generic.
How many shares does Takeda Pharmaceutical Company Limited have in circulation?
The max supply of Takeda Pharmaceutical Company Limited shares is 1.57B.
What is Takeda Pharmaceutical Company Limited Price to Earnings Ratio (PE Ratio)?
Takeda Pharmaceutical Company Limited PE Ratio is 36.43645500 now.
What was Takeda Pharmaceutical Company Limited earnings per share over the trailing 12 months (TTM)?
Takeda Pharmaceutical Company Limited EPS is 112.36 JPY over the trailing 12 months.
Which sector does the Takeda Pharmaceutical Company Limited company belong to?
The Takeda Pharmaceutical Company Limited sector is Healthcare.
Takeda Pharmaceutical Company Limited 4502.T included in indexes
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
---|
Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
---|---|---|---|---|---|---|---|
{{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
Nikkei 300 N300 | 587.56 JPY 3.97 USD |
-0.57
|
— — | 581.72 JPY 3.93 USD | 588.28 JPY 3.97 USD | — - | — — |
Nasdaq Developed Select Leaders NQDMSLC | 1260.81 USD — |
0
|
— — | 1243.71 USD — | 1264.94 USD — | — - | — — |
Nikkei 225 N225 | 39142.46 JPY 264.22 USD |
-0.96
|
— — | 38820.95 JPY 262.05 USD | 39170.35 JPY 264.41 USD | — - | — — |
- {{ link.label }} {{link}}